Kyowa Kirin Co Ltd - ESG Rating & Company Profile powered by AI
The report of Kyowa Kirin Co Ltd employs data from across the internet as well as from public disclosures by Kyowa Kirin Co Ltd. This SDG rating for Kyowa Kirin Co Ltd indicates the company's reporting of the United Nations SDGs. Alternative companies in the scoring peer group for Kyowa Kirin Co Ltd are displayedin the table.
Kyowa Kirin Co Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 7.6; made up of an environmental score of 6.9, social score of 8.0 and governance score of 8.0.
7.6
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 187 | Richter Gedeon Vegyeszeti Gyar Nyrt | 7.7 | High |
| 187 | Vitrolife AB | 7.7 | High |
| 209 | Kyowa Kirin Co Ltd | 7.6 | High |
| 209 | Actinogen Medical Ltd | 7.6 | High |
| 209 | Bajaj Healthcare Ltd | 7.6 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Kyowa Kirin Co Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Kyowa Kirin Co Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes Kyowa Kirin Co Ltd report the average age of the workforce?
Sign up for free to unlockDoes Kyowa Kirin Co Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Kyowa Kirin Co Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes Kyowa Kirin Co Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes Kyowa Kirin Co Ltd offer flexible work?
Sign up for free to unlockDoes Kyowa Kirin Co Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Kyowa Kirin Co Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Kyowa Kirin Co Ltd conduct supply chain audits?
Sign up for free to unlockDoes Kyowa Kirin Co Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Kyowa Kirin Co Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes Kyowa Kirin Co Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes Kyowa Kirin Co Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Kyowa Kirin Co Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Kyowa Kirin Co Ltd disclose water use targets?
Sign up for free to unlockDoes Kyowa Kirin Co Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid Kyowa Kirin Co Ltd have a product recall in the last two years?
Sign up for free to unlockDoes Kyowa Kirin Co Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes Kyowa Kirin Co Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Kyowa Kirin Co Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Kyowa Kirin Co Ltd disclose parental leave metrics?
Sign up for free to unlockDoes Kyowa Kirin Co Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Kyowa Kirin Co Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Kyowa Kirin Co Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes Kyowa Kirin Co Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Kyowa Kirin Co Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Kyowa Kirin Co Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Kyowa Kirin Co Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes Kyowa Kirin Co Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Kyowa Kirin Co Ltd disclose its waste policy?
Sign up for free to unlockDoes Kyowa Kirin Co Ltd report according to TCFD requirements?
Sign up for free to unlockDoes Kyowa Kirin Co Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Kyowa Kirin Co Ltd disclose energy use targets?
Sign up for free to unlockDoes Kyowa Kirin Co Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Kyowa Kirin Co Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Kyowa Kirin Co Ltd
These potential risks are based on the size, segment and geographies of the company.
Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals focused on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; GRAN, a human colony-stimulating factor; and G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia. The company's products also comprise LEUNASE for acute lymphoblastic leukemia; Mitomycin-C, an anticancer antibiotic; Moventig, an oral once daily peripherally acting mu-opioid receptor antagonist for the treatment of opioid induced constipation in adult patients; PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody that targets CC chemokine receptor 4; and REGPARA, an agent for the treatment of secondary hyperparathyroidism. In addition, it offers Romiplate/Nplate, a genetically recombinant protein, which stimulates platelet production through the stimulation of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. Kyowa Kirin Co., Ltd. has strategic research alliance with Harvard University; and an agreement with Amgen to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was founded in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.